I can't wait for you to discuss the phamacokinetics of Rapamycin dosing. I'm on 1mg/day Rapamune, 6,1/2yrs post liver transplant (U W Med). I converted from tacrolimus 1,1/2yrs ago. I would love to find more on cultivating an ecosystem of Transplant Tolerance from different dosing protocols.
You didn't talk about bacterial pneumonia and reduced immunity from taking rapamycin? Anecdotally...in my small community who have tried rapamycin, I know of several who had bacterial pneumonia 2 to 4 weeks after taking it at 5mg per week.
@@fivestar5897 Do you have a source that provides an "honest" discussion on the "immunosuppressant dangers of rapamycin "? If you consider this channel to be "a promotional channel for rapamycin", why are you here?
I would love to know if Rapamycin could help rejuvenate veins with Chronic Venous Insufficiency . I went from hiking many miles a day to an overnight halt of my walking due to severe knee swelling (nothing wrong with my knees.) Weighed 123 lbs this morning and I workout regularly. Always have for the most part. 🤷🏼♀️
Doctor GPT says, "Maybe?" ### Misconceptions to Avoid: 1. **Rapamycin as a Cure-All:** Some might think rapamycin is a universal solution for all health issues due to its broad applications. 2. **Direct Impact on Veins:** There's a misconception that rapamycin directly strengthens veins or prevents venous issues without considering its broader cellular mechanisms. 3. **Immediate Effects:** People often expect immediate results from medications like rapamycin, not accounting for the time it takes to observe significant changes. ### How Rapamycin Affects Chronic Venous Insufficiency **Mechanism of Action:** Rapamycin, also known as sirolimus, is primarily known for its immunosuppressive and anti-proliferative properties. It inhibits the mammalian target of rapamycin (mTOR) pathway, which is crucial in cell growth, proliferation, and survival. **Potential Benefits for Chronic Venous Insufficiency (CVI):** 1. **Anti-inflammatory Effects:** - CVI is often associated with chronic inflammation in the venous walls and surrounding tissues. Rapamycin's anti-inflammatory properties could potentially reduce inflammation, leading to improved venous function. 2. **Endothelial Cell Function:** - The mTOR pathway is significant in endothelial cell function and vascular smooth muscle cell proliferation. By modulating this pathway, rapamycin might help maintain or restore proper endothelial function, which is critical in managing CVI. 3. **Reduction of Fibrosis:** - Chronic inflammation in CVI often leads to fibrosis, which can impair venous function. Rapamycin has been shown to reduce fibrosis in various tissues, potentially benefiting patients with CVI by minimizing fibrotic changes in the venous walls. **Challenges and Considerations:** 1. **Systemic Effects:** - While rapamycin has potential benefits, its systemic immunosuppressive effects could lead to an increased risk of infections and other complications, particularly in long-term use. 2. **Dosage and Administration:** - Determining the appropriate dosage and delivery method for targeting venous insufficiency specifically is crucial. Over- or under-dosing could either negate the benefits or increase the risk of adverse effects. 3. **Clinical Evidence:** - Currently, direct clinical evidence supporting the use of rapamycin for CVI is limited. Most of the potential benefits are extrapolated from its effects on related cellular and inflammatory pathways. More targeted clinical trials are necessary to validate its efficacy and safety in CVI patients. ### Conclusion Rapamycin could theoretically benefit chronic venous insufficiency through its anti-inflammatory, anti-fibrotic, and endothelial cell function modulation properties. However, its use must be carefully considered against potential systemic effects and lack of direct clinical evidence. Further research and clinical trials are essential to establish its role in treating CVI.
Dasatinib + Quercetin (senolytic) also raises Klotho levels n human urine. The biochemical mechanism of this is unknown. However, if Rapa also increases Klotho, perhaps it could be used as a marker for healthspan improvement or even life-span improvement, but would require validation with other life-extension modalities. I wonder why no one has included Klotho in their biological clocks (or have they?)
I (68 y/o female) was taking Dasatinib 50 mg x 3 days every other month along with 6 mg Rapamycin weekly. Dasatinib gave me bad headaches. Had to stop.
@@terri6723 I stop rapamycin when I go through a course of D (100 mg) + Q (1.5 g). No scientific reason for stopping rapa during a course of D+Q but I didn't want any potential drug-drug interaction
Rapa has been off patent for years, one of the main reasons no organization will finance large trials. Optispan can't get rich off a drug it doesn't own. That's a good argument against a conflict of interest.
@optispan the claim was not that of having a financial stake in rapamycin The claim is that this channel is a promotional channel for rapamycin: 1. the first video promotes rapamycin as the "gold standard" for longevity interventions 2. non-Rapa interventions such as NR or NMN are 'disqualified' using preposterous arguments that they damage kidneys when in fact it is the (over)dosing that is the danger 3. rapamycin is foundational to the $25000/year Optispan "memberships" being sold It is most unfortunate to see Matt now acting in Sinclair-esque ways, though $25000 per person is a lot of money
@optispan I shared a detailed factual rebuttal but it was censored/deleted. So it has come to that, promote a product and censor those who may wish to engage in discussion.
I can't wait for you to discuss the phamacokinetics of Rapamycin dosing. I'm on 1mg/day Rapamune, 6,1/2yrs post liver transplant (U W Med). I converted from tacrolimus 1,1/2yrs ago. I would love to find more on cultivating an ecosystem of Transplant Tolerance from different dosing protocols.
I am definitely interested as well ! No doctor in France would know and give you it. It is important to reach this information
What do you think of Greg Fahy's experiments?
Is CRP test an accurate way to determine the level of inflammation throughout the body?
What do you think of the Rapamycin clinical trial that Dr Brad Stanfield is organising?
You didn't talk about bacterial pneumonia and reduced immunity from taking rapamycin? Anecdotally...in my small community who have tried rapamycin, I know of several who had bacterial pneumonia 2 to 4 weeks after taking it at 5mg per week.
don't expect honest discussion, about immunosuppressant dangers of rapamycin or otherwise, this is a promotional channel for rapamycin
@@fivestar5897 Do you have a source that provides an "honest" discussion on the "immunosuppressant dangers of rapamycin "? If you consider this channel to be "a promotional channel for rapamycin", why are you here?
Matt, Are you cycling your dosage? Like 3 weeks on 1 week off etc. just wondering.
I would love to know if Rapamycin could help rejuvenate veins with Chronic Venous Insufficiency . I went from hiking many miles a day to an overnight halt of my walking due to severe knee swelling (nothing wrong with my knees.) Weighed 123 lbs this morning and I workout regularly. Always have for the most part. 🤷🏼♀️
Doctor GPT says, "Maybe?"
### Misconceptions to Avoid:
1. **Rapamycin as a Cure-All:** Some might think rapamycin is a universal solution for all health issues due to its broad applications.
2. **Direct Impact on Veins:** There's a misconception that rapamycin directly strengthens veins or prevents venous issues without considering its broader cellular mechanisms.
3. **Immediate Effects:** People often expect immediate results from medications like rapamycin, not accounting for the time it takes to observe significant changes.
### How Rapamycin Affects Chronic Venous Insufficiency
**Mechanism of Action:**
Rapamycin, also known as sirolimus, is primarily known for its immunosuppressive and anti-proliferative properties. It inhibits the mammalian target of rapamycin (mTOR) pathway, which is crucial in cell growth, proliferation, and survival.
**Potential Benefits for Chronic Venous Insufficiency (CVI):**
1. **Anti-inflammatory Effects:**
- CVI is often associated with chronic inflammation in the venous walls and surrounding tissues. Rapamycin's anti-inflammatory properties could potentially reduce inflammation, leading to improved venous function.
2. **Endothelial Cell Function:**
- The mTOR pathway is significant in endothelial cell function and vascular smooth muscle cell proliferation. By modulating this pathway, rapamycin might help maintain or restore proper endothelial function, which is critical in managing CVI.
3. **Reduction of Fibrosis:**
- Chronic inflammation in CVI often leads to fibrosis, which can impair venous function. Rapamycin has been shown to reduce fibrosis in various tissues, potentially benefiting patients with CVI by minimizing fibrotic changes in the venous walls.
**Challenges and Considerations:**
1. **Systemic Effects:**
- While rapamycin has potential benefits, its systemic immunosuppressive effects could lead to an increased risk of infections and other complications, particularly in long-term use.
2. **Dosage and Administration:**
- Determining the appropriate dosage and delivery method for targeting venous insufficiency specifically is crucial. Over- or under-dosing could either negate the benefits or increase the risk of adverse effects.
3. **Clinical Evidence:**
- Currently, direct clinical evidence supporting the use of rapamycin for CVI is limited. Most of the potential benefits are extrapolated from its effects on related cellular and inflammatory pathways. More targeted clinical trials are necessary to validate its efficacy and safety in CVI patients.
### Conclusion
Rapamycin could theoretically benefit chronic venous insufficiency through its anti-inflammatory, anti-fibrotic, and endothelial cell function modulation properties. However, its use must be carefully considered against potential systemic effects and lack of direct clinical evidence. Further research and clinical trials are essential to establish its role in treating CVI.
You need to see a vascular surgeon.
Dasatinib + Quercetin (senolytic) also raises Klotho levels n human urine. The biochemical mechanism of this is unknown. However, if Rapa also increases Klotho, perhaps it could be used as a marker for healthspan improvement or even life-span improvement, but would require validation with other life-extension modalities. I wonder why no one has included Klotho in their biological clocks (or have they?)
I (68 y/o female) was taking Dasatinib 50 mg x 3 days every other month along with 6 mg Rapamycin weekly. Dasatinib gave me bad headaches. Had to stop.
@@terri6723 I stop rapamycin when I go through a course of D (100 mg) + Q (1.5 g). No scientific reason for stopping rapa during a course of D+Q but I didn't want any potential drug-drug interaction
Another promotional video for Rapamycin, at least this channel is consistent
We have zero financial stake in rapamycin.
Rapa has been off patent for years, one of the main reasons no organization will finance large trials. Optispan can't get rich off a drug it doesn't own. That's a good argument against a conflict of interest.
@optispan the claim was not that of having a financial stake in rapamycin
The claim is that this channel is a promotional channel for rapamycin:
1. the first video promotes rapamycin as the "gold standard" for longevity interventions
2. non-Rapa interventions such as NR or NMN are 'disqualified' using preposterous arguments that they damage kidneys when in fact it is the (over)dosing that is the danger
3. rapamycin is foundational to the $25000/year Optispan "memberships" being sold
It is most unfortunate to see Matt now acting in Sinclair-esque ways, though $25000 per person is a lot of money
@@askingwhy123 it is foundational to their 25K/year memberships that they are selling and hence promoting
@optispan I shared a detailed factual rebuttal but it was censored/deleted. So it has come to that, promote a product and censor those who may wish to engage in discussion.